Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.
Eur J Med Chem. 2023 Mar 5;249:115153. doi: 10.1016/j.ejmech.2023.115153. Epub 2023 Jan 27.
In modern drug discovery and development, the prodrug approach has become a crucial strategy for enhancing the pharmacokinetic profiles of drugs. A prodrug is a chemical compound, which gets metabolized into a pharmacologically active form (drug) inside the body after its administration. In the current work, we report 'smProdrugs' (http://cheminfolab.in/databases/prodrug/), which is one of the first exclusive databases on small molecule prodrugs. It stores the structures, physicochemical properties and experimental ADMET data manually curated from literature. SmProdrugs lists 626 small molecule prodrugs and their active compounds with the above mentioned experimental data from 1808 research articles and 61 patents have been stored. The information page of each record gives the structures and properties of the prodrug and the active drug side by side which makes it easy for the user to instantly compare them. The structural modifications in the prodrug/active drugs are highlighted in a different colour for easy comparison. Experimental data has been curated from the downloaded PubMed and patent articles and were catalogued in a tabular form with more than 25 fields under sub-sections i) name and structures of the prodrugs and their active compounds, ii) mode of activation of the prodrug and enzyme/biocatalyst involved in the conversion, iii) indications/disease, iv) pharmacological target, v) experimental pharmacokinetic properties such as solubility, absorption, volume of distribution, half-life, clearance etc. and vi) information on the purpose/gain from the prodrug strategies. Considering the ever expanding utility of the prodrug approach smProdrugs will be of great use to the scientific community working on rational design of small molecule prodrugs.
在现代药物发现和开发中,前药方法已成为增强药物药代动力学特征的关键策略。前药是一种化学化合物,在给药后在体内被代谢为具有药理活性的形式(药物)。在目前的工作中,我们报告了“smProdrugs”(http://cheminfolab.in/databases/prodrug/),这是第一个专门针对小分子前药的数据库之一。它存储了从文献中手动整理的结构、物理化学性质和实验 ADMET 数据。SmProdrugs 列出了 626 种小分子前药及其活性化合物,这些化合物具有上述实验数据,来自 1808 篇研究文章和 61 项专利的数据已被存储。每个记录的信息页面并排显示前药和活性药物的结构和性质,使用户可以轻松地立即进行比较。前药/活性药物中的结构修饰用不同颜色突出显示,便于比较。实验数据是从下载的 PubMed 和专利文章中整理出来的,并以表格形式分类,在各个子部分下有超过 25 个字段:i)前药和其活性化合物的名称和结构,ii)前药的激活方式以及参与转化的酶/生物催化剂,iii)适应症/疾病,iv)药理学靶标,v)实验药代动力学性质,如溶解度、吸收、分布容积、半衰期、清除率等,vi)关于前药策略的目的/收益的信息。考虑到前药方法的应用不断扩大,SmProdrugs 将对从事小分子前药合理设计的科学界有很大的帮助。